Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
1199 participants
OBSERVATIONAL
2024-09-26
2027-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Prospective Cohort Study of Myasthenia Gravis in China
NCT06006832
Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China
NCT04535843
Myasthenia Gravis Registry in China
NCT06241521
Clinical Prognosis and Progression of Myasthenia Gravis Patients
NCT04101578
A Prospective Cohort Study Of Myasthenia Gravis
NCT04674605
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Patients must have the following data to be enrolled in this study:
* MGFA classification
* MG-ADL score
2. MG patients or their legal guardians/representatives are able to sign the Informed Consent Form (ICF).
Exclusion Criteria
2. Patients who are currently participating in an interventional clinical trial cannot be enrolled in this study.
0 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fudong Shi, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Beijing Tiantan Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Beijing, , China
Research Site
Chengdu, , China
Research Site
Fuzhou, , China
Research Site
Guangzhou, , China
Research Site
Guiyang, , China
Research Site
Harbin, , China
Research Site
Hebei, , China
Research Site
Henan, , China
Research Site
Inner Mongolia, , China
Research Site
Jiangsu, , China
Research Site
Lanzhou, , China
Research Site
Nanning, , China
Research Site
Qingdao, , China
Research Site
Taiyuan, , China
Research Site
Tianjin, , China
Research Site
Ürümqi, , China
Research Site
Wenzhou, , China
Research Site
Wuhan, , China
Research Site
Xi'an, , China
Research Site
Yinchuan, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D9030R00001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.